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Abstract
Introduction Mammography screening reduces breast cancer
mortality through earlier diagnosis but may convey further
benefit if screening is associated with optimized treatment
through multidisciplinary medical care. In Norway, a national
mammography screening program was introduced among
women aged 50 to 69 years during 1995/6 to 2004. Also
during this time, multidisciplinary breast cancer care units were
implemented.
Methods We constructed three cohorts of breast cancer
patients: 1) the pre-program group comprising women
diagnosed and treated before mammography screening began
in their county of residence, 2) the post-program group
comprising women diagnosed and treated through
multidisciplinary breast cancer care units in their county but
before they had been invited to mammography screening; and
3) the screening group comprising women diagnosed and
treated after invitation to screening. We calculated Kaplan-
Meier plots and multivariable Cox proportional hazard models.
Results We studied 41,833 women with breast cancer. The
nine-year breast cancer-specific survival rate was 0.66 (95%CI:
0.65 to 0.67) in the pre-program group; 0.72 (95%CI: 0.70 to
0.74) in the post-program group; and 0.84 (95%CI: 0.80 to
0.88) in the screening group. In multivariable analyses, the risk
of death from breast cancer was 14% lower in the post-program
group than in the pre-program group (hazard ratio 0.86;
(95%CI: 0.78 to 0.95, P = 0.003)).
Conclusions After nine years follow-up, at least 33% of the
improved survival is attributable to improved breast cancer
management through multidisciplinary medical care.
Introduction
In many Western countries, breast cancer incidence is
increasing, while mortality rates remain stable or are decreas-
ing [1]. In the US, incidence rose slightly between 1987 and
2001 and then stabilized, with some evidence of decline
through 2003. In contrast, death rates from breast cancer
have been falling since 1990 [2]. Two obvious factors have
contributed to this success: widespread use of systemic adju-
vant treatment [3-5] and earlier diagnosis due to mammogra-
phy screening [6,7]. The relative contributions of these factors
are likely to differ between settings, population subgroups,
and time periods. However, attempts to quantify them through
statistical modelling suggest that in the US, adjuvants and
mammography each contribute about half to the mortality
reduction [8]. A Swedish study found about an 18% reduction
in mortality due to factors other than screening [9].
Formation of dedicated multidisciplinary breast cancer care
teams has become widespread but the potential increase in
survival from this approach is not well understood. Indeed, the
quantification of such a possible benefit is methodologically
challenging, because it requires access to valid information on
CI: confidence interval; HR: hazard ratio.Breast Cancer Research    Vol 11 No 4    Kalager et al.
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relevant confounding factors and opportunities for complete
long-term follow-up of large cohorts of patients. The unique
health care system, the staggered implementation of the
screening program, and complete coverage of the breast can-
cer registry in Norway allow us to overcome such challenges.
Materials and methods
Norwegian health care system and the Cancer Registry 
of Norway
To allow all citizens equal access to public health care,
charges for public medical services in Norway are kept low. As
there is hardly any private in-patient service in Norway, hospi-
tal-provided medical services are population-based and
mostly pertain to the county in which the patient lives. Patients
rarely choose hospitals outside their county of residence, and
there is no private care for breast cancer treatment [10].
Since 1952, there has been compulsory reporting of all cancer
diagnoses to the nationwide Cancer Registry of Norway.
Patients are referred to by their unique national registration
number, which is assigned to all residents in Norway and
includes the date of birth. The Registry also records informa-
tion on age at diagnosis, date of diagnosis, and pathological
Tumor Noduli Metastasis classification coded, according to
current International Union Against Cancer guidelines [11].
Stage is coded in the Registry as I to IV: I = localized cancer,
II = regional cancer, III = cancer fixed to either skin or the chest
wall, and IV = cancers with distant metastases. The primary
treatment is recorded as the type of surgical procedure per-
formed. Information on primary adjuvant hormone therapy,
chemotherapy, and radiation therapy is reported once by the
treating surgeon and recorded as 'given' or 'not given'. Axillary
surgery (axillary dissection or sentinel-node dissection) was
not recorded in the database until 1993.
Mammography screening program
Following an official report that recommended a nationwide
mammography screening program in Norway [12], a pilot
project was started in November 1995. The plan was to invite
all women aged 50 to 69 years living in four out of the 19 coun-
ties in Norway to undergo biannual mammography screening.
These four counties comprised 40% of the eligible female
population. After two years, the Norwegian government
decided on a stepwise expansion to reach national coverage.
Thus, in each county, multidisciplinary breast cancer care units
were established that met the criteria of the Quality Assurance
Manual of the Norwegian Breast Cancer Screening Program
[13] based on the European guidelines for quality assurance
in breast cancer screening and diagnosis [14]. To ensure
high-quality medical care, as defined by the national require-
ments outlined in the quality assurance manual, each breast
cancer care unit is continuously monitored by the Cancer Reg-
istry, including site visits every second year. During 1995 to
2004, all Norwegian counties were gradually included in the
mammography screening program (Figure 1). Since February
2004, the program has been fully implemented, and all women
between the ages of 50 and 69 years living in Norway are
invited to undergo screening.
The national program is organized with 26 stationary and four
mobile mammography screening units [13]. Women eligible
for screening are identified by the Central Population Registry
of Norway using their national registration number. Personal
invitations are mailed to each eligible woman, suggesting an
appointment time. One reminder is mailed to non-attendees
[15]. Two-view mammograms, offered biannually, are read
independently by two radiologists in accordance with the
European guidelines for quality assurance [14]. Data on all
women eligible for the screening program are stored in a cen-
tral database at the Cancer Registry of Norway.
Prior to inclusion in the breast cancer screening program,
each county was required to establish a multidisciplinary
breast cancer care unit in accordance with the European
guidelines [14] to ensure uniform management of disease. As
a result, diagnosis and treatment became centralized within
the county, and only dedicated teams were involved in patient
care. Each breast cancer care unit covers a total population of
100,000 to 500,000. These units consist of multidisciplinary
teams of radiologists, radiographers, pathologists, surgeons,
oncologists, and nurses in charge of diagnosis, staging, treat-
ment, and post-treatment surveillance of breast cancer
patients. The teams meet weekly to discuss the management
of newly diagnosed patients in their county. Prior to the estab-
lishment of these breast cancer care units, patients were diag-
nosed and treated by available radiologists, pathologists,
surgeons, and oncologists, with no organized meetings or dis-
cussion of patients.
Study cohorts
We retrieved data on all women diagnosed with a first invasive
primary breast cancer in Norway between 1 November, 1985
and 31 December, 2004 from the Cancer Registry database.
We achieved complete follow-up through 2004 by means of
record linkages based on the national registration number.
Information from the Central Population Registry allowed cen-
soring for those individuals who emigrated. For deceased indi-
viduals, the National Death Registry provided information on
date and cause of death.
We defined three mutually exclusive cohorts of women with
breast cancer based on their county of residence, information
on the date of the first invitation to mammography screening,
and the date of diagnosis of the primary breast cancer.
The pre-program group comprises all women diagnosed
before the mammography screening program began in their
county of residence (November 1985 to February 2004).Available online http://breast-cancer-research.com/content/11/4/R44
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The post-program group comprises all women resident in the
counties where breast cancer care units were established and
the screening program had started, but who had not yet been
invited to mammography screening and whose breast cancer
was diagnosed between November 1995 and December
2004.
The screening group comprises women who were diagnosed
with breast cancer after they had been invited to mammogra-
phy screening.
Thus, the only difference between the first two groups is that
women in the post-program group received medical care
through the breast cancer care units, while women in the pre-
program group did not. Because the screening group is influ-
enced by lead-time bias and length-biased sampling, their sur-
vival estimates are not directly comparable with those of the
pre-program and the post-program groups, where as the latter
two groups both comprise clinically detected breast cancer.
As a corollary, our main comparisons were confined to the pre-
and post-program groups. However, the screening group was
included to allow a conservative estimate of the proportional
contribution of improved management as distinct from screen-
ing detection.
Statistical analyses
We used the Pearson chi-squared test to compare the two
groups according to age, stage of breast cancer, and treat-
ment. The overall and breast cancer-specific survival rates
were calculated using life table techniques, illustrated by Kap-
lan-Meier plots, and compared using the log-rank test. Censor-
ing occurred at date of emigration, date of death from causes
other than breast cancer, or the end of the follow-up period,
whichever came first. To facilitate comparison, we restricted
follow-up in the pre-program group in accordance with follow-
up period in the post-program group. Logically, the counties
most recently included in the screening program had a shorter
follow-up time. We restricted follow-up time in the pre-pro-
gram group to the actual follow-up time in the post-program
group in each county. Hence, for the most recently enrolled
county, follow-up time was 0.9 years in the post-program era,
and we restricted follow-up time in the pre-program group
accordingly. Time trends of breast cancer survival were calcu-
lated for each county.
Hazard ratios were calculated using Cox proportional hazard
models. We used the likelihood ratio statistics to compare
groups. We adjusted for age at diagnosis by four age catego-
ries: younger than 40, 40 to 49, 50 to 69, and 70 years and
older. We further adjusted for time trends, county of resi-
dence, and the following treatment variables: surgery (yes/no),
Figure 1
The staggered implementation of the Norwegian breast cancer screening program in the different groups of counties during the study period The staggered implementation of the Norwegian breast cancer screening program in the different groups of counties during the study period. The 
three study groups are shown in different colours. A = The counties of Rogaland, Oslo, Hordaland, and Akershus; B = Telemark, Agder, Troms, and 
Finnmark; C = Østfold, Nordland, Buskerud, and Trøndelag; D = Oppland and Møre og Romsdal; E = Sogn og Fjordane and Hedmark; F = Vestfold.Breast Cancer Research    Vol 11 No 4    Kalager et al.
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hormone treatment (yes/no), chemotherapy (yes/no), and radi-
ation therapy (yes/no). Because trends in survival differed by
county, we adjusted for county and time trends by including
county-specific trend parameters in the model. We did not
adjust for stage at diagnosis due to the likelihood of stage
migration [14]. The proportional hazard assumption was
tested by both graphical methods and Schoenfeld residuals.
All test statistics are two-tailed and P values < 0.05 are con-
sidered statistically significant. All calculations are performed
with the statistical package Stata 9.2 (StataCorp, Tx, USA).
The research protocol was approved by the ethical review
board of the Cancer Registry of Norway. Individual informed
consent was not requested.
Results
Baseline characteristics
We identified a total of 41,833 women diagnosed with a pri-
mary invasive breast cancer from 1 November, 1985 to 31
December, 2004. During follow-up through 2004, 16,494
(39.4%) women died, for 9953 (60.3%) of whom breast can-
cer was listed as the underlying cause of death. A total of
6960 women were diagnosed after they had been invited to
the screening program. This left a total of 34,873 women to be
included in the main comparisons between the pre- and post-
program group. Of these, 26,883 (77.1%) individuals belong
to the pre-program group, while 7990 (22.9%) comprise the
post-program group. The mean follow-up times in the pre- and
post-program groups were 3.8 years and 3.2 years, respec-
tively. The maximum duration of follow-up was 9.1 years in
both groups.
Table 1 shows baseline characteristics for the pre-program
and post-program groups of breast cancer patients. The pro-
portion between 50 and 69 years of age was smaller in the
post-program group than in the pre-program group because
only women in that age group are invited to mammography
screening. Thus, these patients were included in the screening
group. Compared with the pre-program period, more patients
in the post-program era received tamoxifen and radiation ther-
apy. In addition, chemotherapy was given more often to
women younger than 50 years than to those aged over 50
years in the post-program period. Approximately 10% of all
patients had no surgery; most of these women were older than
69 years (Table 1).
Survival analyses
Breast cancer survival rates were significantly different across
the three cohorts (P < 0.001; Figure 2). Compared with the
pre-program group, estimated nine-year survival was 6%
higher in the post-program group and 18% higher among
women who had been invited to mammography screening
(Table 2). In exploratory analyses stratified by stage of disease,
the five- and nine-year survival was consistently higher in the
post-program than in the pre-program group (data not shown).
Table 1
Baseline characteristics of women with incident breast cancer 
in Norway 1985 to 2004, diagnosed before (pre-program) and 
after (post-program) introduction of population-based 
mammography screening program in their county of residence
Pre-program
n = 26,883
Post-program
n = 7990
Characteristic Number (%) Number (%)
Age (years 0)
<40 1492 5.6 658 8.2
40 to 49 4533 16.9 2119 26.5
50 to 69 10,339 38.5 1383 17.3
≥ 70 10.519 39.1 3830 47.9
Stage*
I 13,035 48.5 3977 50.0
II 10,338 38.5 3201 40.1
III 1414 5.3 348 4.4
IV 1750 6.5 444 5.6
unknown# 346 1.3 20 0.3
Pathologic size
1 (0 to 20 mm) 7782 28.9 3162 39.6
2 (>20 to 50 mm) 5657 21.0 2270 28.4
3 (>50 mm) 621 2.3 190 2.4
4 (growth) 1429 5.3 443 5.5
unknown# 11,394 42.4 1925 24.1
Treatment‡
Radiation therapy 5323 19.8 2942 36.8
unknown# 5113 19.0 1847 23.1
Hormone therapy 8230 30.6 3128 39.2
unknown# 4810 17.9 2041 25.5
Chemotherapy 6792 25.3 2044 25.6
unknown# 5523 20.5 2678 33.5
Surgery 24,694 91.9 6997 87.6
BCT 2160 8.0 2045 25.6
Mastectomy 20,661 76.9 4885 61.1
SN** 572 4.2 1859 23.3
Ax** 10,356 75.6 4486 56.2
#unknown represents either missing values or values we were not 
able to classify.
* staging is based on the classification of tumor-stage in the Cancer 
Registry of Norway: I = localized cancer, II = regional cancer 
(represents no of node 0 positive tumors), III = cancer fixed to either 
skin or to the chest wall, IV = cancers with distant metastases.
‡the treatment variable indicates that treatment was given.
**surgical procedures in the axilla were not specified until 1993 in 
the database; percentage is calculated based on breast cancer 
patients diagnosed from 1993 to 2004.
Ax = axillary dissection; BCT = breast-conserving surgery; SN = 
sentinel-node dissection.Available online http://breast-cancer-research.com/content/11/4/R44
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Five-year survival for women diagnosed in successive two-
year intervals increased gradually with a more marked improve-
ment following introduction of mammography screening pro-
gram in 1995 to 1996 (Figure 3).
Compared with the pre-program period, women diagnosed in
the post-program period experienced a statistically significant
14% reduction in breast cancer-specific death rate after
adjustment for age, calendar year of diagnosis, county of resi-
dence, and treatment variables (hazard ratio (HR) 0.86; 95%
confidence interval (CI) 0.78 to 0.95; P = 0.003; Table 3). An
additional analysis included only those individuals in whom all
treatment variables were available (n = 23,111), with no signif-
icant difference in HR compared with the main analysis (HR
0.83; 95% CI 0.72 to 0.95; P = 0.009). In an additional anal-
ysis of only the four pilot counties, we noted a 19% reduction
in breast cancer-specific death rate when adjusting for age,
calendar year of diagnosis, county of residence, and treatment
variables (HR 0.81; 95% CI 0.71 to 0.91; P = 0.001). In anal-
yses without adjusting for calendar year of diagnosis, we
found a 24% reduction (HR 0.76; 95% CI 0.70 to 0.82; P <
0.001).
Discussion
Our data show a substantial survival benefit among women
diagnosed with breast cancer after introduction of the Norwe-
gian breast cancer screening program but before they had
been invited to mammography. We consider this benefit likely
to be due to a combination of earlier diagnosis through
increased awareness and optimization of standard breast can-
cer care through establishment of breast cancer care units.
Thus, the implementation of the larger breast cancer screening
program, including a re-organization of the breast cancer
health care system, significantly increased survival independ-
ent of the primary task of the program, namely mammography
screening.
The fundamental prerequisite for our analysis was the large
overlap in time between the pre- and post-program group, due
to the step-wise introduction of mammography screening in all
Norwegian counties during a nine-year period. This overlap
minimized potential confounding due to factors that might
affect the survival of breast cancer in the population over time.
Additional strengths of our study include its nationwide
design, large size, complete long-term follow-up of patients,
and the homogeneous public health care system in Norway,
which offers uniform health care management to all women
diagnosed with breast cancer in the same county at a certain
time.
Our study has several potential limitations. We were not able
to take into account mammography screening through private
Figure 2
Survival curves for the different groups Survival curves for the different groups.Breast Cancer Research    Vol 11 No 4    Kalager et al.
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medical services, which might confound our survival analyses
if it affects the women in pre- and post-program groups differ-
ently. Confined mostly to the larger cities of Norway, private
mammography screening has been available since the mid-
1980s. However, there is no evidence that it has become
more common during the study period [16]. If the improvement
in breast cancer survival was caused mainly by improved
breast cancer awareness or private screening, we would
expect smaller, less advanced cancers in the post-program
group. However, the stage distribution was strikingly similar in
the pre- and post-program periods (Table 1), although stage
migration due to more sensitive diagnostic methods in recent
years might have affected this comparison.
We saw an improvement in breast cancer survival in all stages,
which might represent a real survival benefit, but may also have
Figure 3
Five-year survival of breast cancer by two-year increments throughout the study period for all women except those invited to mammography screen- ing Five-year survival of breast cancer by two-year increments throughout the study period for all women except those invited to mammography screen-
ing. The curve is presented with 95% confidence interval.
Table 2
Five- and nine-year breast cancer-specific survival in the pre-and post-program group and screening group
5-year 9-year
Group Survival 95% CI Survival 95% CI
Pre-program group 0.76 0.75 to 0.77 0.66 0.65 to 0.67
Post-program group 0.80 0.79 to 0.81 0.72 0.70 to 0.74
Screening group 0.91 0.90 to 0.92 0.84 0.80 to 0.88
CI = confidence interval.Available online http://breast-cancer-research.com/content/11/4/R44
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been influenced by stage migration [17]. In contrast to other
studies [18,19], ours did not adjust for stage, because stage
migration might entail differential misclassification between
the pre- and post-program groups. Despite the overlap in time
between the two groups, we adjusted for time trends and
treatment variables, with no significant differences in treatment
variables between the two groups. The adjustment for time
trend may give the most reliable results in our model, as the
treatment-related data at the Registry are only recorded once,
and this is most often performed at the time of the primary sur-
gery, before treatment is completed.
Furthermore, 40% of the eligible women in Norway were
offered mammography screening from the start of the program
in 1995/6. To explore the effect of overall improvement in
breast cancer mortality during the time period 1985 to 2004,
we performed separate analysis for the women living in the
four pilot counties. In this comparison, the pre- and post-pro-
gram groups are not parallel in time. Here, we found a 19%
reduction in breast cancer mortality after adjusting for calen-
dar year of diagnosis and a 24% reduction when we did not
adjust for calendar year of diagnosis. This 5% difference might
be attributable to a gradual improvement in diagnosis and
treatment, enhanced breast cancer awareness, improved gen-
eral health, and other factors not easily measured over the time
period. We noted a gradual improvement in breast cancer
mortality throughout the time period, so we chose to adjust for
calendar year of diagnosis, not to exaggerate the effect of
implementation of multidisciplinary breast cancer care.
It is impossible to reliably attribute the observed survival ben-
efit to any specific component of optimal clinical management.
New surgical treatments, such as breast-conserving surgery,
combined with radiation therapy, sentinel node techniques,
and axillary node dissection do not improve the survival rate of
patients with breast cancer [20-22]. However, several studies
have shown a positive association between surgical experi-
ence (measured in number of procedures performed) and sur-
vival [23-25]. The proportion of patients treated with
chemotherapy across all age groups is stable throughout the
study period. However, it is conceivable that such treatment
was given more systematically to patients who benefited most
when they were managed by multidisciplinary team work. Not
surprisingly, we found that women who did not have surgery
had poorer outcomes.
To the best of our knowledge, the present study provides the
first empirical data on non-mammography benefits of mam-
mography screening programs. Consistent with our findings,
however, a computer-based modelling by Blanks and col-
leagues estimated a 15% reduction in mortality by factors
beyond mammography screening in a national mammography
screening program in the UK [26]. The survival curves of
breast cancer patients diagnosed by screening are not directly
comparable with survival curves of women diagnosed clini-
Table 3
Hazards ratios from Cox regression models with 95% confidence interval and corresponding P values, of breast cancer survival 
comparing post-program group with pre-program group
Univariable Multivariable
Category HR 95% CI P value HR* 95% CI P value
Pre-program 1.00 ref 1.00 Ref
Post-program 0.83 0.77 to 0.88 <0.001 0.86 0.78 to 0.95 0.003
Age-categorized (years)
0 to 39 1.00 ref
40 to 49 0.60 0.53 to 0.67 <0.001
50 to 69 0.73 0.66 to 0.81 <0.001
≥ 70 0.98 0.89 to 1.08 0.75
Surgery performed# 0.17 0.16 to 0.19 <0.001
Chemotherapy given# 0.97 0.96 to 0.98 <0.001
Hormone therapy given# 1.03 1.01 to 1.04 <0.001
Radiation given# 1.00 0.99 to 1.02 0.63
*Adjusted for county of residence and calendar year of diagnosis.
# Reference categories: surgery not performed; chemotherapy not given; hormone therapy not given; radiation not given, respectively.
CI = confidence interval; HR = hazard ratio.Breast Cancer Research    Vol 11 No 4    Kalager et al.
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cally. In the former category, survival time becomes exagger-
ated by lead-time bias, length bias sampling, and possibly also
by selection bias and overdiagnosis bias. Because we are una-
ble to adjust for screening survival biases, the proportional
contribution by factors other than screening is underesti-
mated. In addition, the proportion of women aged 50 to 69
years was higher in the screening group than the pre-screen-
ing group, which may lead to further underestimation of the dif-
ference in breast cancer survival among women in the two
groups, because women diagnosed at this age have a higher
breast cancer survival than women younger than 50 years and
older than 69 years of age. Based on nine years of follow-up,
we found that at least 33% ((0.72 to 0.66)/(0.84 to 0.66)) of
the increase in survival following the introduction of the mam-
mography screening programs is attributable to better man-
agement of breast cancer.
Conclusions
Our results suggest an independent improvement in breast
cancer survival produced by reorganizing breast cancer care,
probably combined with earlier diagnosis through increasing
awareness of early breast cancer symptoms. Because differ-
ences in prognosis and survival are seen for a wide variety of
malignancies, between geographic areas, and among different
socioeconomic classes, it is intriguing to believe that this
effect may apply not only to the management of breast cancer
patients, but to a variety of other malignancies as well.
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